| A multicenter, open label, balanced, randomized, two treatment, two-period crossover, multi-dose, steady state, bioequivalence study of Nevirapine 400 mg prolonged release tablets, compared to Viramune 400 mg prolonged release tablets in adult HIV1 infected patients. | A multicenter, open label, balanced, randomized, two treatment, two-period crossover, multi-dose, steady state, bioequivalence study of Nevirapine 400 mg prolonged release tablets,Manufactured by Amneal Pharmaceuticals Pvt. Ltd. India compared to Viramune 400 mg prolonged release tablets, Marketed by Boehringer Ingelheim International GmbH, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany in adult HIV1 infected patients under fasting condition. - 15-VIN-479 | CTRI/2015/10/006244 |
